Get the Stockscreener App
16.36
3.03%
-0.565
Organon Co stock is traded at $16.36, with a volume of 5.24M.
It is down -3.03% in the last 24 hours and down -10.30% over the past month.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$16.92
Open:
$16.74
24h Volume:
5.24M
Relative Volume:
2.55
Market Cap:
$4.14B
Revenue:
$6.35B
Net Income/Loss:
$1.05B
P/E Ratio:
7.1419
EPS:
2.29
Net Cash Flow:
$458.00M
1W Performance:
-8.09%
1M Performance:
-10.30%
6M Performance:
-16.34%
1Y Performance:
+23.36%
1-Day Range:
$15.98
$16.85
1-Week Range:
$15.98
$19.05
52-Week Range:
$10.84
$23.10
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Relative Strength Alert For Organon - Nasdaq
Organon updates outlook as FDA delays VTAMA label expansion - MSN
Organon’s VTAMA Cream FDA Review Extended to 2025 - TipRanks
Organon stock on watch as FDA delays VTAMA label (OGN:NYSE) - Seeking Alpha
FDA extends Organon's VTAMA cream review to March 2025 - Investing.com
Organon's SWOT analysis: stock outlook amid VTAMA potential and biosimilar growth - Investing.com UK
Organon & Co. (NYSE:OGN) Trading Down 4.4%Should You Sell? - MarketBeat
Organon & Co (OGN) Stock Price Down 6.38% on Nov 4 - GuruFocus.com
The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - Simply Wall St
Organon China’s License and Supply Agreement with Shanghai Bao Pharmaceuticals - Global Legal Chronicle
(OGN) Technical Pivots with Risk Controls - Stock Traders Daily
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28 - Yahoo Finance
Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN
Private Management Group Inc. Has $36.23 Million Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
FDA accepts Organon BLA for Prolia/Xgeva biosimilar - MSN
Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023) - Yahoo Finance
Organon & Co. (NYSE:OGN) to Issue $0.28 Quarterly Dividend - MarketBeat
Organon & Co (OGN) Shares Up 5.61% on Oct 31 - GuruFocus.com
Organon: Q3 Earnings Snapshot - The Advocate
Organon & Co. Reports Strong Third Quarter 2024 Results - TipRanks
Organon Co earnings missed by $0.03, revenue topped estimates - Investing.com Australia
Organon (OGN) Q3 Earnings and Revenues Beat Estimates - MSN
Earnings call: Organon announced a revenue of $1.6 billion - Investing.com
Earnings call: Organon announced a revenue of $1.6 billion By Investing.com - Investing.com UK
Organon Reports Results for the Third Quarter Ended September 30, 2024 - BioSpace
Organon & Co Q3 2024 Earnings: EPS Soars to $1.38, Revenue Hits $1.582 Billion, Surpassing Estimates - GuruFocus.com
Organon & Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Organon Q3 2024 Earnings Preview: Dermavant purchase in focus - MSN
FDA accepts Henlius and Organon's biosimilar application By Investing.com - Investing.com South Africa
Organon Q3 2024 Earnings Preview: Dermavant purchase in focus (NYSE:OGN) - Seeking Alpha
FDA accepts Organon BLA for Prolia/Xgeva biosimilar (NYSE:OGN) - Seeking Alpha
FDA accepts Henlius and Organon's biosimilar application - Investing.com
Dermavant acquisition expands Organon’s dermatology portfolio - MSN
Organon Completes Acquisition of Dermavant - citybiz
Organon completes Dermavant Sciences acquisition - Investing.com
Organon completes Dermavant Sciences acquisition By Investing.com - Investing.com UK
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - StockTitan
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
Organon & Co. (NYSE:OGN) Short Interest Up 28.2% in October - MarketBeat
Do Options Traders Know Something About Organon (OGN) Stock We Don't? - MSN
Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline - Yahoo Finance
Organon & Co trades in the red for seven straight sessions - MSN
Organon & Co. (OGN) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 - Benzinga
Organon (Thailand) Ltd. promotes health and elevates women’s quality of life, creating change at the WEPs Awards 2024 - Nation Thailand
Organon (OGN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
YieldBoost Organon From 6.4% To 11.4% Using Options - Nasdaq
With 80% institutional ownership, Organon & Co. (NYSE:OGN) is a favorite amongst the big guns - Simply Wall St
Itching to Expand: Organon to Acquire Dermavant - Law Street Media
Organon Pride Network leaders share insights on ERG leadership and workplace inclusion - attitude.co.uk
Entrepreneurs triumph at Organon and Flat6Lab’s Women's Health Accelerator demo day - ZAWYA
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):